Special Issue

G-Protein-Coupled Receptors as Therapeutic Targets for CNS Disorders

Message from the Guest Editors

G-protein-coupled receptors (GPCRs) represent the largest family of membrane receptors in the human genome and play pivotal roles in cellular signaling across various physiological systems. In the central nervous system (CNS), GPCRs are critical for regulating neurotransmitter release, synaptic plasticity, neuronal excitability, and neuroinflammation. Accumulating evidence has highlighted the strong relationship between GPCR dysfunction and the pathophysiology of numerous CNS disorders, including schizophrenia, depression, anxiety, Parkinson's disease, Alzheimer's disease, and epilepsy. Moreover, there is growing evidence linking GPCRs to brain cancer development, in particular glioblastoma tumor progression. In this Special Issue, authors are invited to submit original articles dealing with the discovery and/or development of subtype selective or multitarget ligands targeting GPCRs that are potentially useful for the treatment of CNS diseases. Review articles focusing on recent findings in this area of investigation will also be welcome.

Guest Editors

Dr. Fabio Del Bello

Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, 62032 Camerino, Italy

Dr. Wilma Quaglia

Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, 62032 Camerino, Italy

Deadline for manuscript submissions

24 July 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/251946

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

